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Abstract
Herein we report the fabrication of protein (bovine serum albumin, BSA) particles which were
rendered transiently insoluble using a novel, reductively labile disulfide-based cross-linker. After
being cross-linked, the protein particles retain their integrity in aqueous solution and dissolve
preferentially under a reducing environment. Our data demonstrates that cleavage of the cross-
linker leaves no chemical residue on the reactive amino group. Delivery of a self-replicating RNA
was achieved via the transiently insoluble PRINT protein particles. These protein particles can
provide new opportunities for drug and gene delivery.
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Delivering promising biological therapeutics to the desired location in the body in a safe and
effective fashion is one of the key challenges in medicine. Proteins as the matrices for drug
delivery particles have many advantages including bio-degradability, biocompatibility and
amenability to surface modification.1 Drug carriers using proteins as matrices for the
delivery of small molecule drugs and biological cargos, such as plasmid DNA and siRNA,
are being extensively studied.2,3,4 Each of these applications would benefit from having
protein-based particles that dissolve slowly in a controlled and desirable manner.5 Herein,
we report the synthesis of size- and shape-specific protein micro- and nano-particles using a
top-down particle fabrication technique called PRINT. Our approach involves the design
and synthesis of a novel“traceless ” cross-linker that renders protein-based particles
transiently insoluble in aqueous solutions. We also report the cytoplasmic delivery of a self-
replicating RNA via PRINT protein particles stabilized by this novel cross-linker.
Protein particles are often made through costly and complicated processes which include
wet-milling, spray-freeze-drying, micro-emulsion, micro-encapsulation, or supercritical
fluid methods.6,7,8 Frequently, these procedures result in highly heterogeneous
polydispersed spherical or granular particles and do not allow control over particle size or
shape.9 PRINT is a platform technology that is an off-shoot of soft lithography that enables
the molding of micro- and nano-particles having precisely controlled size, shape, chemical
composition and surface functionality.10,11 PRINT has been transitioned to a continuous
roll-to-roll fabrication technique that can enable the scale-up of particle production to
practical levels for applications in the clinic.
Dry microspheres or nanospheres composed of proteins are usually instantaneously soluble
when placed into aqueous solutions.9 A couple of strategies have been reported that
maintain the stability of protein-based particles: i) thermal cross-linking, which causes the
formation of intermolecular disulfide bridges between free thiol groups;12 ii) the use of non-
reversible chemical cross-linkers, such as 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC), glutaraldehyde, formaldehyde etc.;7,13 and iii) the use of reversible cross-linkers like
Lomant's reagent, dithiobis[succinimidyl propionate] (DSP), which can be cleaved upon
exposure to certain biologic conditions.5 Thermal cross-linking involves the thermal
denaturation of a given protein at high temperature and cannot be applied to the delivery of
fragile cargos. The use of non-reversible chemical cross-linkers introduces permanent cross-
linkages between individual protein molecules which limit the release of encapsulated
cargos. Reversible cross-linkers can be cleaved upon exposure to certain biologic conditions
but leaves a chemical residue —a potential neoepitope—on the protein after cleavage of the
disulfide bond (Scheme 1a).14 If the released protein from the particles has molecular
pendants attached, it may elicit undesirable immune responses towards foreign antigens,
which may induce adverse health effects.15,16 Inspired by the chemistry Wender et al.
developed to release drugs in their original state from a pro-drug form,17,18 we designed a
“traceless” reversible cross-linker that leaves no pendant chemical residues on the molecule
it reacts with after cleavage of the linker. We have applied the use of such transient,
traceless chemical cross-linkers to achieve stabilization of protein particles fabricated using
the PRINT technology.
Based on our previous efforts,9 a melt-solidification strategy was employed in the
fabrication of PRINT protein particles (Figure S1). Lactose and glycerol (for use as
plasticizers) are mixed with the protein of choice, in this case BSA, to form the pre-particle
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material that readily “flows” when heated. Serum albumin was chosen in this study for two
reasons: 1) As the most abundant blood plasma protein it is essential for the transport of
many physiological molecules and 2) it also has the advantage of being readily available.1 In
particular, bovine serum albumin (BSA) was used in this study due to its easy accessibility
and cost effectiveness for our proof-of-concept study. The processing temperature used to
fabricate protein-based particles in this study can be as low as 60 °C, which avoids the
potential degradation of the delicate biological therapeutics we are investigating.
Taking advantage of the PRINT process, a series of BSA particles were fabricated in the
size range of 200 nm to several micrometers (Figure S2). In this study, cylindrical particles
with both diameter and height as 1 µm were fabricated with a pre-particle composition
containing 37.5 wt % of BSA, 37.5 wt% of α-D-lactose and 25.0 wt% of glycerol. In order
to determine the final composition after the purification step, particles were analyzed by
high-performance liquid chromatography (HPLC) coupled with evaporative light scattering
detection (ELSD). The dry particles were found to contain 86.7±1.1 wt% of BSA, 10.2±1.7
wt% of lactose and 3.1±0.7 wt% of glycerol (Table S1). The protein particles, at this stage,
are fully soluble when brought into contact with water (Figure S3), which indicated the
necessity for a cross-linker to transiently stabilize the albumin particles.
In order to utilize protein-based particles for therapeutic applications, they are usually
stabilized with cross-linkers, which can be cleaved under certain physiological stimuli.19
The cytoplasm of cells is known for its high concentration of reduced glutathione (GSH)
compared to the extracellular environment (GSH concentration differs by 1000 folds
intracellularly and extracellularly).20 In this study, we take advantage of the reducing
environment in the cytoplasm of cells by introducing a disulfide-based cross-linker that
should trigger the intracellular dissolution of our protein particles. Wender et al. developed a
disulfide based pro-drug linker, which contains a carbonate group instead of conventionally
used ester linkage, to release the drug in its original state.17 This chemistry has also been
applied to develop a fluorogenic probe for thiol detection and a pro-drug for intracellular
delivery.21,22,23 Inspired by previous work, we developed a novel cross-linker dithio-
bis(ethyl 1 H-imidazole-1-carboxylate) (DIC) for this study. Compared to DSP, DIC has
several advantages. Imidazoles were introduced as the leaving groups in DIC to replace the
highly reactive NHS as in DSP in order to better control the rate of the cross-linking reaction
and the cross-linking density on the particle surface. Furthermore, DIC is a “traceless”
reversible cross-linker, which does not leave any molecular pendants after disulfide cleavage
(Scheme 1b). As a control, a nondisulfide non-degradable crosslinker, 2,2'-
oxybis(ethane-2,1-diyl) bis(1H-imidazole-1-carboxylate) (OEDIC) was also synthesized
(Scheme 1c).
To demonstrate the ability of DIC to release the amino group in its original form after
cleavage of the disulfide, we utilized tyramine as a model, a small molecule with only one
amino group. Two tyramine molecules were reacted with DIC in isopropanol, which
completely simulates the cross-linking conditions for protein-based particles (Scheme S2).
To prove this unique property of DIC, the commercially available disulfide crosslinker DSP
was used as a control in this study. The dimer products were denoted as tyramine-DIC and
tyramine-DSP, respectively. Both compounds were treated with 50 mM of dithiothreitol
(DTT) in phosphate buffer saline (PBS) to cleave the disulfide bond. Gas chromatography
mass spectrum (GC-MS) results indicated that after cleavage of the disulfide bond, tyramine
was regenerated from tyramine-DIC. No peak of tyramine was observed with tyramine-DSP
(Figure S4). In addition, 1H-NMR and high-resolution mass spectrometry confirmed the
structure of tyramine recovered after DTT treatment of tyramine-DIC. (SI)
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The PRINT albumin particles were cross-linked with DIC and OEDIC at different cross-
linker concentrations (based on a constant particle concentration) and a quantitative study of
particle dissolution was performed (Figure 1). From these data, it was apparent that the
particles cross-linked with the disulfide linker DIC retained their stability in PBS and
preferentially dissolved under reducing conditions. The rate of particle dissolution can be
effectively modulated by changing the cross-linker concentration.
In order to demonstrate the capability of the particles to deliver biological cargos to a
reducing cellular compartment, we selected an RNA molecule capable of self-replication
and encoding Chloramphenicol Acetyl Transferase (CAT) protein exclusively in the
cytoplasm. Successful delivery of this RNA into the cytoplasm of Vero cells would yield
expression of CAT protein which can be detected by enzyme-linked immunosorbent assay
(ELISA) using antigen-specific antibodies. Particles were fabricated using the PRINT
process containing the Replicon RNA cargo (1 wt%), BSA, lactose and glycerol and were
stabilized using the DIC cross-linker. The isoelectric point of BSA is 4.75, resulting in
cross-linked particles with a negative ζ-potential. Based on the previous studies, cells
preferentially internalize positively charged particles.11 TransIT®-mRNA transfection
reagent (TransIT) was mixed with BSA particles in order to introduce positive charges to
BSA particle surface to enhance cell uptake and endosomal escape (Table S3). As a result of
internalization of the particles coated with TransIT into Vero cells, CAT protein was
generated (Figure 2). CAT protein production via delivery of PRINT particles was
competitively comparable to the same amount of RNA directly transfected by TransIT. As a
negative control, blank particles (no RNA encapsulated) did not induce any protein
expression. Furthermore, to rule out CAT protein expression induced by complexing of
extracellular RNA and TransIT reagents, DIC-crosslinked BSA / RNA particles were
incubated in PBS for 4 h at 37 °C, particles were pelleted by centrifugation and the
supernatant was dosed to cells with TransIT. Absence of CAT protein expression was
observed confirming particle mediated delivery of RNA. Analysis using confocal
microscopy was also carried out to visually confirm the generation of CAT protein (Figure
S6).
In summary, a novel cross-linker strategy was able to effectively render the PRINT protein
particles transiently insoluble in aqueous solutions. The cross-linked particles preferentially
dissolved under reducing conditions and the rate of particle dissolution can be controlled by
adjusting the cross-linker concentration. By coating the RNA-loaded particles with TransIT,
CAT protein was expressed via delivery of PRINT particles. These precisely engineered
protein particles showed great potential for drug and gene delivery.
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(a) SEM image of BSA particles (cross-linked at 4.4 mM of DIC) after incubation with
water, scale bar represents 10 μm. (b) Dissolution profile of cross-linked BSA particles in
PBS containing 5 mM GSH (GSH, squares with solid lines) and PBS only (PBS, triangles
with dotted lines), A, B and C: particles cross-linked at 4.4 mM, 6.6 mM, and 9.9 mM of
DIC, respectively; D: particles cross-linked at 4.4 mM of OEDIC. The error bars stand for
the standard deviation calculated from triplicates.
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CAT protein generated from Vero cells (2×104 cells per well) measured by ELISA. Black:
CAT RNA standards with TransIT, purple: blank particles with TransIT, orange: CAT RNA
containing BSA particles with TransIT, 2, 1 and 0.5μg/mL of particles corresponds to 30, 15
and 7.5 ng/mL of RNA (SI), blue: supernatant from particles incubated in PBS for 4 h at
37°C with TransIT. Error bars represent standard deviation calculated from four wells.
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(a) Structure of DSP and reaction scheme for protein cross-linking and dissolution; (b)
Structure of DIC and reaction scheme for protein cross-linking and dissolution; (c) Structure
of OEDIC
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